Search

Displaying results 2611 - 2620 of 10000 in total
  1. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … NET is the primary mechanism regulating the biological effects of norepinephrine (NE) on the body.

  2. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment

  3. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    When administered as the prodrug uridine triacetate, uridine can be used by essentially all cells to make uridine nucleotides, which compensates for the genetic deficiency in synthesis in patients with … Furthermore, orotic acid crystals in the urine can cause episodes of obstructive uropathy.

  4. Drug

    Lutein

    go.drugbank.com/drugs/DB00137
    ApprovedNutraceutical

    Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. … Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids.

  5. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.

  6. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]

  7. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  8. Drug

    Lactobacillus plantarum

    go.drugbank.com/drugs/DB11360
    Investigational

    *Lactobacillus plantarum* is a member of Lactobacillus, or lactic acid bacteria, that it is widely used in the food industry as a microbial starter and probiotic microorganism. … It is considered to be one of versatile species that carry out fermentative and metabolic processes, while exhibiting an antagonistic activity against pathogenic and spoilage microorganisms.

    Mixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADET
  9. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels. … This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL

  10. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. … numbness in the lower leg and walking disability associated with acquired lumbar spinal canal stenosis as an additional indication in 2001.

    Categories: Prostaglandins E